NEW YORK, NY / ACCESSWIRE / October 18, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Valaris plc (NYSE: VAL)
Class Period: April 11, 2019 to July 31, 2019
Lead Plaintiff Deadline: October 21, 2019
The lawsuit alleges that throughout the class period, Valaris plc made materially false and/or misleading statements and/or failed to disclose that: (i) the Company was plagued by a weak ultra-deepwater segment, massive cash usage, and significant negative cash flow; (ii) the foregoing was reasonably likely to have a material negative impact on the Company's second quarter 2019 results; (iii) the merger leading to Valaris's establishment could not deliver on its touted benefits; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in VAL: http://www.kleinstocklaw.com/pslra-1/valaris-plc-loss-submission-form?id=3980&from=1.
Altria Group, Inc. (NYSE: MO)
Class Period: December 20, 2018 to September 24, 2019
Lead Plaintiff Deadline: December 2, 2019
The lawsuit alleges Altria Group, Inc. made materially false and/or misleading statements and/or failed to disclose during the class period that: (i) Altria had conducted insufficient due diligence into JUUL prior to the Company's $12.8 billion investment, or 35% stake, in JUUL; (ii) Altria consequently failed to inform investors, or account for, material risks associated with JUUL's products and marketing practices, and the true value of JUUL and its products; (iii) all of the foregoing, as well as mounting public scrutiny, negative publicity, and governmental pressure on e-vapor products and JUUL made it reasonably likely that Altria's investment in JUUL would have a material negative impact on the Company's reputation and operations; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in MO: http://www.kleinstocklaw.com/pslra-1/altria-group-inc-loss-submission-form?id=3980&from=1.
Myriad Genetics, Inc. (NASDAQ: MYGN)
Class Period: September 2, 2016 to August 13, 2019
Lead Plaintiff Deadline: November 26, 2019
The complaint alleges that during the class period Myriad Genetics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Myriad's product, GeneSight, lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (ii) the U.S. Food and Drug Administration ("FDA") had requested changes to GeneSight and questioned the validity of the test's purported benefits; (iii) Myriad had been in ongoing discussions with the FDA regarding the FDA's requested changes to GeneSight; (iv) Myriad's acquisition of Counsyl-and thereby, Foresight-caused the Company to incur the risk of suffering from lower reimbursement for its expanded carrier screening tests, which had the potential to, and actually did, materialize into a material negative impact on the Company's revenue; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in MYGN: http://www.kleinstocklaw.com/pslra-1/myriad-genetics-inc-loss-submission-form?id=3980&from=1.
Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: The Klein Law Firm
View source version on accesswire.com: